STRIDES PHARMA SCIENCE
|
STRIDES PHARMA SCIENCE Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 60.34 | 389.90 | -7.68 | -22.44 | -51.25 |
| CEPS(Rs) | 84.29 | 65.28 | 7.59 | 1.37 | -26.87 |
| DPS(Rs) | 5.00 | 4.00 | 2.50 | 1.50 | - |
| Book NAV/Share(Rs) | 337.08 | 276.83 | 230.95 | 242.83 | 262.48 |
| Tax Rate(%) | 14.08 | 15.92 | -25.36 | 19.32 | 27.32 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.95 | 11.25 | 9.40 | 6.17 | -0.40 |
| EBIT Margin(%) | 11.99 | 10.38 | 2.72 | -0.40 | -8.93 |
| Pre Tax Margin(%) | 9.46 | 6.87 | -1.89 | -4.58 | -12.25 |
| PAT Margin (%) | 8.13 | 5.77 | -2.36 | -3.70 | -8.90 |
| Cash Profit Margin (%) | 10.99 | 8.48 | 1.15 | 0.20 | -4.53 |
| Performance Ratios | |||||
| ROA(%) | 9.25 | 7.21 | -2.41 | -3.52 | -6.99 |
| ROE(%) | 20.31 | 17.52 | -6.67 | -10.15 | -18.49 |
| ROCE(%) | 18.57 | 16.56 | 3.47 | -0.49 | -9.49 |
| Asset Turnover(x) | 1.14 | 1.25 | 1.02 | 0.95 | 0.78 |
| Sales/Fixed Asset(x) | 2.28 | 2.46 | 1.96 | 1.91 | 1.75 |
| Working Capital/Sales(x) | 9.85 | 13.98 | 67.85 | 43.06 | -106.88 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.44 | 0.41 | 0.51 | 0.52 | 0.57 |
| Receivable days | 64.34 | 60.35 | 73.17 | 73.25 | 79.41 |
| Inventory Days | 75.20 | 61.86 | 68.12 | 67.80 | 81.35 |
| Payable days | 218.23 | 173.66 | 191.36 | 230.40 | 267.95 |
| Valuation Parameters | |||||
| PER(x) | 15.54 | 1.72 | - | - | - |
| PCE(x) | 11.13 | 10.25 | 103.13 | 209.18 | -12.90 |
| Price/Book(x) | 2.78 | 2.42 | 3.39 | 1.18 | 1.32 |
| Yield(%) | 0.53 | 0.60 | 0.32 | 0.52 | - |
| EV/Net Sales(x) | 2.08 | 1.71 | 2.42 | 1.37 | 1.86 |
| EV/Core EBITDA(x) | 9.39 | 9.08 | 15.14 | 9.69 | 51.09 |
| EV/EBIT(x) | 11.92 | 10.63 | 56.91 | -201.23 | -12.01 |
| EV/CE(x) | 2.11 | 1.80 | 2.07 | 1.01 | 0.85 |
| M Cap / Sales | 1.78 | 1.35 | 1.85 | 0.70 | 1.01 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 6.43 | 17.36 | 5.47 | 20.13 | -7.41 |
| Core EBITDA Growth(%) | 24.89 | 38.49 | 19.51 | 365.23 | -83.70 |
| EBIT Growth(%) | 15.15 | 344.76 | 760.20 | 94.73 | -211.81 |
| PAT Growth(%) | 40.33 | 384.50 | 37.68 | 51.31 | -294.53 |
| EPS Growth(%) | -84.52 | 5,174.47 | 65.76 | 56.22 | -271.23 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.54 | 0.70 | 1.14 | 1.27 | 1.18 |
| Current Ratio(x) | 1.25 | 1.20 | 1.03 | 1.05 | 0.99 |
| Quick Ratio(x) | 0.68 | 0.70 | 0.64 | 0.67 | 0.64 |
| Interest Cover(x) | 4.75 | 2.96 | 0.59 | -0.10 | -2.69 |
| Total Debt/Mcap(x) | 0.19 | 0.29 | 0.34 | 1.07 | 0.90 |
Compare Financial Ratios of peers of STRIDES PHARMA SCIENCE
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| STRIDES PHARMA SCIENCE | ₹9,435.7 Cr | 4.1% | -0.4% | 19.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹463,180.0 Cr | 1.6% | -1% | 22.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹243,302.0 Cr | 1.7% | 10.1% | 49.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,623.0 Cr | 1.5% | -1.2% | 38.2% | Stock Analytics | |
| CIPLA | ₹114,554.0 Cr | 0.7% | -3.5% | -10.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,741.0 Cr | -1.3% | 0.1% | -7.8% | Stock Analytics | |
STRIDES PHARMA SCIENCE Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| STRIDES PHARMA SCIENCE | 4.1% |
-0.4% |
19.5% |
| SENSEX | -0.9% |
-1.5% |
-5.8% |
You may also like the below Video Courses
